Erton ZB, Erkan D, et al.
Current opinion in pharmacology. Date of publication 2022 Aug 1;volume 65():102212.
1. Curr Opin Pharmacol. 2022 Aug;65:102212. doi: 10.1016/j.coph.2022.102212. Epub
2022 May 27.
Treatment advances in antiphospholipid syndrome: 2022 update.
Erton ZB(1), Erkan D(2).
Author information:
(1)Division of Rheumatology, Hospital for Special Surgery, New York, NY, USA.
(2)Barbara Volcker Center for Women and Rheumatic Diseases, Division of
Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY,
USA. Electronic address: erkand@hss.edu.
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized
by thrombosis, pregnancy morbidity, or non-thrombotic manifestations in patients
with persistently positive antiphospholipid antibodies (aPL). Conventional
treatment strategies of antiphospholipid syndrome focuses on antithrombotic
agents, however they are usually not effective for microvascular and
non-thrombotic manifestations of aPL. In parallel to our increased understanding
of the mechanisms of aPL-mediated clinical events, immunosuppression has been
increasingly used in aPL-positive patients. This review focuses on the role of
potential targeted immunosuppressive treatments in APS (B-cell inhibition,
complement inhibition, mechanistic target of rapamycin inhibition, and
traditional rheumatologic disease-modifying agents including hydroxychloroquine)
and future perspectives.
Copyright © 2022. Published by Elsevier Ltd.
DOI: 10.1016/j.coph.2022.102212
PMID: 35636385 [Indexed for MEDLINE]
Conflict of interest statement: Conflict of interest statement Dr. Erkan received
grants/contracts from American College of Rheumatology & European League Against
Rheumatism, Immune Tolerance Network via NIH-NIAID, Exagen, Lupus Clinical Trials
Consortium and GlaxoSmithKline.
